By Nina S. Cauchon, Ph.D., R.A.C., Amgen Inc.; Edward Narke, R.A.C., DS InPharmatics; and Susan Ohorodnik, Ph.D., Envigo
Pharmaceutical regulations need to move from reactive to proactive to keep pace with the rapid rise of emerging technologies and novel modalities.
AAPS reports on salary and employment trend data of its members.
Strengthen your communication and leadership skills.
Simulations based on a branded drug's FDA-submitted data and limited use of a generic are adequate and can help shorten generic development timelines, FDA researchers said during a recent AAPS webinar.
AAPS reviews its progress in 2017.
From polymers for insulin oral delivery to breast cancer drug transporters to novel anticancer drug administration across the blood-brain barrier for brain cancer therapy.
Student Chapter Focus
Did You Know?